INTERNATIONAL SOCIETY OF MICROBIOTA

5th WORLD CONGRESS ON

TARGETING MICROBIOTA
Towards Clinical Revolution

OCTOBER 26-27, 2017 - BERLIN, GERMANY

PROGRAM

WWW.MICROBIOTA-SITE.COM
Dear Colleagues,

On behalf of the members of the scientific committee, we are pleased to inform you about the strategies for our annual meeting: 5th World Congress on Targeting Microbiota, which will be held in Berlin, Germany on October 26-27, 2017.

A substantial amount of evidence has shown that a diverse population of micro-organisms live in our skin, mouth, nose, lungs and intestines, where they play a strategic role in regulating and possibly controlling human health, well-being, metabolism and diseases.

During both days, many oral and poster communications will be presented and will cover many hot topics:

- Microbiota 2017: Recent Advances & Perspectives
- Challenges of microbiota sequencing and analyzing: How to interpret the results?
- Challenges of microbiota-host cross-talk understanding and intestinal microbiome signaling to extraintestinal organs
- Microbiota & medicine of tomorrow: Development of effective therapeutic strategies to manipulate the gut microbiota

During this two-day conference, we will try to answer many questions, among them:

- Can we modulate the quality and diversity of human microbiota?
- How to induce durable beneficial changes in gut microbiota?
- Where is the red line of the gut microbiota manipulation?
- What are the strategic mediators of gut microbiota?
- How to understand better the role of bacterial metabolites?
- What is the perfect microbiota "signature" and how to use it as a biomarker to "predict" and/or treat many diseases?

We very much look forward to seeing you in Berlin for this exciting event.

Prof. Lorenzo Drago
University of Milan, Italy
President of the International Society of Microbiota

Prof. Marvin Edeas
University Paris Descartes, Cochin Institute, France

Prof. Peter Konturek
Thuringia-Clinic Saalfeld, Germany
Co-chairmen of the Scientific Committee
Targeting Microbiota 2017 Congress Speakers

**Microbiota & Mitochondria intertalk in hemodialysis patients**
Marvin Edeas
University Paris Descartes, Institut Cochin, France

**Role of microbiota in Graft-versus-Host Disease (GVHD) and complications of allogeneic stem cell transplantation**
Daniela Weber
Regensburg Universitätsklinikum, Germany

**Skin microbiota approaches: atopic dermatitis versus psoriasis**
Lorenzo Drago
University of Milano, Italy

**Human gut microbiota: from structures to functions**
Hervé Blottière
INRA, France

**Microbiota and autoimmune diseases: a shield or a sword?**
Filippo Cantucci
University of insubria, Italy

**The microbiota, epigenome and transcriptome of colonic inflammation in inflammatory bowel disease**
Marcus Claesson
University College Cork, Ireland

**Novel techniques in microbiota research: from meta-omics to single cells**
Jakob Zimmermann
University of Bern, Switzerland

**Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway**
Indoles from commensal bacteria extend healthspan
Rheinhardt M. Jones
Emory University School of Medicine, USA

**Hemodynamic effects of hydrogen sulfide, indole and tmao-gut bacteria-derived molecules: the role of the gut-blood barrier**
Marcin Ufnal
Medical University of Warsaw, Poland

**Unraveling the gut microbiome of the long-lived naked mole-rat**
Gerd Birkenmeier
University of Leipzig, Germany

**RNA-based stable isotope probing to link structure and function of prebiotics-assimilating intestinal microorganisms**
Markus Egert
Furtwangen University, Germany

**Advances in fecal microbiota transplantation**
Peter Konturek
Teaching Hospital of the University of Jena, Germany

**Metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption**
Federico Rey
University of Wisconsin Madison, USA

**The human infant gut microbiota mobilome**
Knut Rudi
Norwegian University of Life Sciences, Norway

**Dysbiosis profiling and pediatric diseases: pattern correlations and bacterial dysfunctions**
Lorenza Putignani
Bambino Gesù Children’s Hospital and Research Institute, Italy

**Probiotics and bone health: recent scientific advances and perspectives**
Roberto Pacifici
Emory University School of Medicine, USA

**The microbiota-gut-brain axis: modulation by probiotics and antibiotics**
Paul Forsythe
Mc Master University, Canada

**Probiotics as potential therapeutics in the management of metabolic syndrome**
Ryo Aoki
Ezaki Glico Co., Japan

**Intestinal microbiota and primary sclerosing cholangitis: is there any link?**
Johannes Hov
University of Oslo, Norway

**Host genetics driving gut microbiota composition: experimental challenges**
Andy Wullaert
Ghent University, Belgium

**Microbiota, bacterial translocation and inflammation in chronic kidney disease**
Didier Ducoux
CHU Besançon, France
Day 1 – Thursday, October 26

7h45 Welcoming & registration of attendees

8h50 Introduction note by Targeting Microbiota 2017 Chairpersons
Lorenzo Drago, Marvin Edeas, Peter Konturek

**Session 1: Microbiota 2017: Recent Advances & Perspectives**
*Chairpersons: Lorenzo Drago - Marvin Edeas*

9h00 Role of microbiota in Graft-versus-Host Disease (GvHD) and complications of allogeneic stem cell transplantation
Daniela Weber, Regensburg Universitätsklinikum, Germany

9h25 Microbiota and autoimmune diseases: a shield or a sword?
Filippo Canducci, University of Insubria, Italy

9h50 Host genetics driving gut microbiota composition: experimental challenges
Andy Wullaert, University of Ghent, Belgium

10h15 Lactobacilli modulate epithelial cytoprotection through the Nrf2 pathway
*Comments on Indoles from commensal bacteria extend healthspan*
Rheinallt Jones, Emory University School of Medicine, USA

10h45 Coffee Break & Poster Session
*Chairpersons: Gerd Birkenmeier – Paul Forsythe*

11h15 The human infant gut microbiota mobilome
Knut Rudi, Norwegian University of Life Sciences, Norway

11h40 Hemodynamic effects of hydrogen sulfide, indole and TMAO-gut bacteria-derived molecules: the role of the gut-blood barrier
Marcin Ufnal, Medical University of Warsaw, Poland

12h05 Role of nasal microbiota in respiratory recurrent infections
Desiderio Passàli, Honorary President Italian Society of Rhinology, Italy

*Short oral presentations (7 minutes presentation + 3 minutes questions)*

12h20 The gut microbiota is a crucial regulator of local intestinal androgen metabolism in male mice
Hannah Colldén, University of Gothenburg, Sweden

12h30 Antibiotic-induced microbiota perturbation causes gut endocannabinoidome changes, hippocampal neuroglial reorganization and depression in mice
Francesca Guida, University of Campania, Italy

12h40 Lunch Break, Network & Poster Session
Session 2: Challenges of microbiota sequencing and analyzing: How to interpret the results?

Chairpersons: Knut Rudi – Markus Egert - Filippo Canducci

14h00 Human gut microbiota: from structures to functions
Hervé Blottière, INRA, France

14h25 RNA-based stable isotope probing to link structure and function of prebiotics-assimilating intestinal microbiotas
Markus Egert, Furtwangen University, Germany

14h50 Novel techniques in microbiota research: from meta-omics to single cells
Jakob Zimmermann, University of Bern, Switzerland

15h15 Coffee Break, Network & Poster Session

16h00 Short oral presentations for sessions 1 & 2 (7 minutes presentation + 3 minutes questions)

Iron supplements modulate colon microbiota composition and potentiate the protective effects of probiotics in dextran sodium sulfate-induced colitis
Manuela Santos, Canadian Cancer Society Research Institute, Canada

The role of gut microbiota in the development of angiotensin II induced vascular dysfunction in mice
Rebecca Schüler, University Medical Center Mainz, Germany

Exposure to antibacterial chemicals influence oral microbiome composition
Randi Bertelsen, University of Bergen, Norway

The role of the microbiota in neurodegeneration: molecular mechanisms and prospects for gene therapy
Robert Friedland, University of Louisville, USA

Exploring the gut microbiome role in Parkinson’s disease and in primary parkinsonisms
Clarissa Consolandi, National Research Council, Italy

Early life determinants of the fecal resistome
Aimee Marguerite Baumann-Dudenhoeffer, Saint Louis School of Medicine, USA

Newborn meconium microbiota diversity is related to maternal and cord blood lipid profiles
Shu-Ling Chuang, Chelsea & Westminster Hospital, United Kingdom

Identification of a microbial signature of colonic hypersensitivity in IBS-like murine models
Frédéric Antonio Carvalho, University of Auvergne, France

Culture-independent characterization of spores in stool samples
Ekaterina Avershina, Norwegian University of Life Sciences, Norway

Next generation 16S ribosomal RNA gene sequencing reveals intestinal bacterial genera with a potential role in Parkinson’s disease
Severin Weis, Hochschule Furtwangen, Germany

Applying quality engineering principles to enhance reproducibility of longitudinal metagenomics studies
Héloïse Breton, DNA Genotek, Canada

Design of microbiome cohort studies – lessons learned from preparatory phase
Petra Videnska, Masaryk University, Czech Republic

A commensal gut bacteria MRX0004 alleviates inflammatory responses in a severe asthma model through reduction of neutrophil infiltration to the lung
Emma Jane Raftis, 4D Pharma PLC, United Kingdom

18h10 End of the first day

20h30 Targeting Microbiota Dinner at Steigenberger Hotel Berlin
Appointment in the lobby of the hotel. If you would like to participate, please register online or contact the staff on site.
Day 2 – Friday, October 27

8h25 Opening of the second day

**Session 3: Challenges of microbiota-host cross-talk understanding and intestinal microbiome signaling to extraintestinal organs**

*Chairpersons: Peter Konturek - Hervé Blottière*

8h30 Microbiota & mitochondria intertalk in hemodialysis patients  
*Marvin Edeas, University Paris Descartes, Institut Cochin, France*

8h55 Microbiota, bacterial translocation and inflammation in chronic kidney disease  
*Didier Ducloux, CHU Besançon, France*

9h20 Intestinal microbiota and primary sclerosing cholangitis: is there any link?  
*Johannes Hov, University of Oslo, Norway*

9h45 The microbiota, epigenome and transcriptome of colonic inflammation in inflammatory bowel disease  
*Marcus Claesson, University College Cork, Ireland*

10h10 Coffee Break, Network & Poster Session

10h55 Dysbiosis profiling and pediatric diseases: pattern correlations and bacterial dysfunctions  
*Lorenza Putignani, Bambino Gesù Children's Hospital and Research Institute, Italy*

11h20 The microbiota-gut-brain axis: modulation by probiotics and antibiotics  
*Paul Forsythe, Mc Master University, Canada*

11h45 Skin microbiota approaches: atopic dermatitis versus psoriasis  
*Lorenzo Drago, University of Milano, Italy*

12h10 Short oral presentations (7 minutes presentation + 3 minutes questions)

- Are quorum sensing peptides the missing link between microbiota and disease?  
  *Evelien Wynendaele, Ghent University, Belgium*

- The neonatal transfer of intestinal microbiota partially reverses microbiota dysbiosis in rats with intra-uterine growth retardation  
  *Catherine Michel, INRA-Université de Nantes, France*

- Effects of 5-fluorouracil chemotherapy on colon inflammation, gut microbiota, and adverse physiological outcomes  
  *Alexander Theodore Sougiannis, University of South Carolina School of Medicine, USA*

- Modulation of skeletal muscle function by gut microbiota dysbiosis and reseeding  
  *Kévin Nay, INRA, France*

12h50 Lunch Break, Network & Poster Session
**International Society of Microbiota**

**Session 4: Microbiota & medicine of tomorrow: Development of effective therapeutic strategies to manipulate the gut microbiota**

*Chairpersons: Rheinallt Jones - Federico Rey*

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14h00</td>
<td>Advances in fecal microbiota transplantation</td>
<td>Peter Konturek, Teaching Hospital of the University of Jena, Germany</td>
</tr>
<tr>
<td>14h25</td>
<td>Metabolic, epigenetic, and transgenerational effects of gut bacterial choline consumption</td>
<td>Comments on the social ties linked with gut microbiota</td>
</tr>
<tr>
<td>14h50</td>
<td>Probiotics and bone health: recent scientific advances and perspectives</td>
<td>Roberto Pacifici, Emory University School of Medicine, USA</td>
</tr>
<tr>
<td>15h15</td>
<td>Unraveling the gut microbiome of the long-lived naked mole-rat</td>
<td>Gerd Birkenmeier, University of Leipzig, Germany</td>
</tr>
<tr>
<td>15h40</td>
<td>Coffee Break &amp; Poster Session</td>
<td></td>
</tr>
<tr>
<td>16h00</td>
<td>Probiotics as potential therapeutics in the management of metabolic syndrome</td>
<td>Ryo Aoki, Ezaki Glico Co., Japan</td>
</tr>
<tr>
<td>16h25</td>
<td>Short oral presentations (7 minutes presentation + 3 minutes questions)</td>
<td>Can dietary probiotics reduce human stress via the microbiome-gut-brain axis?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>SYN-004 (Ribaxamase) protects the diversity of the gut microbiome in patients receiving intravenous ceftriaxone treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Exploring the microbial taxonomic and metabolic alterations during faecal microbiota transplantation for the treatment of clostridium difficile infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice</td>
</tr>
<tr>
<td></td>
<td></td>
<td>The influence of ketogenic diet in gut microbial diversity of obese Mexican adults with type 2 diabetes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cross-talk between the microbiota and their sisters, the mitochondria: the real cause of mitochondrial health or dysfunction?</td>
</tr>
<tr>
<td>17h25</td>
<td>Health Optimization Medicine (HOMe): a framework to include microbiota and mitochondria in clinical practice</td>
<td>Theodore Achacoso, BioBalance Wellness Institute and Health Optimization, USA</td>
</tr>
<tr>
<td>17h40</td>
<td>Concluding remarks by Peter Konturek</td>
<td></td>
</tr>
<tr>
<td>18h00</td>
<td>End of Targeting Microbiota 2017</td>
<td></td>
</tr>
</tbody>
</table>